May 2, 2013

Q1 2013 business EPS(1) impacted by exclusivity losses in prior year Growth platforms(2) sales increased 8.6%(3)

 

Q1 2013 business EPS(1) impacted by exclusivity losses in prior year Growth platforms(2) sales increased 8.6%(3)

Commenting on the Group’s performance in Q1 2013, Sanofi Chief Executive Officer, Christopher A. Viehbacher said, “As expected, the loss of exclusivity of Plavix®, Avapro® and Eloxatin® in the course of 2012 in the U.S. had a negative impact on Q1 results. However, our growth platforms(2) continue to deliver strong results with diabetes, vaccines, and Genzyme all achieving double-digit growth. The early launch trends for Aubagio® and Auvi-QTM in the U.S. are encouraging, regulatory approvals were granted for Lyxumia®, Zaltrap® and HexyonTM in the EU, and we received positive CHMP opinion for Aubagio®. Moreover, we look forward to the Phase III data releases for several pipeline projects later this year, including our new insulin glargine formulation and alirocumab. The Group expects to resume growth in the second half of 2013.